Gland Pharma is looking at complex injectables segment, contract development, and manufacturing of biosimilars to fuel near term growth. The company has made good progress in the R&D field for planned submission batches for complex injectables to be filed in the current financial year. The company is on track to make four complex injectable filings in this financial year. The company's near-term focus remains on establishing a strong portfolio of complex injectables. It is also looking at acquisition opportunities to help expedite the development process. Installation of new lines catering to suspensions and hormonal products has been completed.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.
